Home » Picture Gallery » MyMedicalRecords to Amend Walgreens Complaint
Ihren XING-Kontakten zeigen

MyMedicalRecords to Amend Walgreens Complaint

LOS ANGELES, CA — (Marketwired) — 07/01/13 — (OTCQB: MMRF), through its wholly owned subsidiary MyMedicalRecords, Inc. (collectively, “MMR”), today announced that it will seek a stipulation or order to file an amended complaint against Walgreens Co. to include claims for infringement of its “Method for Providing a User with a Service for Accessing and Collecting Prescriptions” patent currently in the process of being issued under Notice of Allowance application number 13/714,720 which the Company received on June 19, 2013. The Prescription Management patent is directed toward online access and management of prescriptions in retail pharmacies, mass merchandisers, hospitals and others with pharmacies inside. The patent covers how consumers, patients, physicians and other healthcare professionals send prescriptions to the pharmacy, access prescriptions from a pharmacy, schedule prescription refills, send reminders regarding prescription refills including by text or email, and identify adverse drug interactions by analyzing prescription medications. Based on trends offering consumers the ability to manage prescriptions online, the Company believes this patent to be extremely relevant to its business of selling its products and services and/or licensing its patented intellectual property to healthcare professionals and others including retail pharmacies such as:

– Walgreens
– Rite Aid
– CVS
– Safeway ?
– Wal-Mart
– Sam-s Club
– Target

The list also includes numerous other retailers offering similar services. The Company also sees its newest health IT patent as helping drive revenue to its Prepaid Personal Health Record card and intellectual property pertaining to the use of prescription drug treatment in clinical trials.

MMRGlobal already has seven issued U.S. patents pertaining to health information technologies, including U.S. Patent Nos. 8,301,466; 8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240, as well as additional applications and continuation applications involving inventions pertaining to , Patient Portals and other Electronic Health Record systems in twelve additional countries including Australia, Singapore, New Zealand, Mexico, Japan, Canada, China, Hong Kong, South Korea, Israel, and European nations. The Company-s health IT patent portfolio was the subject of a May 2, 2013 report on Personal Health Records that concluded that the value of the Company-s U.S. patents could reach between $800 million to $1.1 billion in revenue (at .

For additional information regarding the MyMedicalRecords, Inc. patent litigation matters, contact Ted Ward at Liner Grode Stein Yankelevitz Sunshine Regenstreif & Taylor LLP at (310) 500-3384.

MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records (“PHRs”) and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user-s account. The Company-s professional offering, , is designed to give physicians- offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, the Company acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId/Specifid vaccine clinical trials for the treatment of B-Cell Non-Hodgkin-s lymphoma. To learn more about MMRGlobal, Inc. visit . View demos and video tutorials of the Company-s products and services at .

All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property enforcement actions, infringement claims or litigation, intellectual property licenses, and future performance, management-s expectations, beliefs, intentions, estimates or projections, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMR-s actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as “need,” “possibility,” “potential,” “intend,” “offer,” “development,” “if,” “negotiate,” “when,” “begun,” “believe,” “achieve,” “will,” “estimate,” “expect,” “maintain,” “plan,” and “continue,” or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, monetize and protect our patent portfolio for both MMR-s health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk MMR-s products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market-s acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in MMR-s filings with the Securities and Exchange Commission, including disclosures about relationship with the Michael Bass Group since 2009. MMR is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Michael Selsman
Public Communications Co.
(310) 922-7033

You must be logged in to post a comment Login


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de Bloggeramt.de blogoscoop